Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Buy” by Brokerages

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has received a consensus rating of “Buy” from the eight ratings firms that are currently covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $43.17.

A number of analysts have weighed in on the company. Leerink Partnrs upgraded Oruka Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 17th. TD Cowen began coverage on Oruka Therapeutics in a research report on Monday, September 16th. They set a “buy” rating on the stock. Jefferies Financial Group started coverage on Oruka Therapeutics in a report on Friday, September 13th. They issued a “buy” rating and a $40.00 price target for the company. Stifel Nicolaus assumed coverage on shares of Oruka Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $49.00 price objective on the stock. Finally, Wedbush restated an “outperform” rating and set a $40.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, November 19th.

Institutional Investors Weigh In On Oruka Therapeutics

Large investors have recently modified their holdings of the stock. FMR LLC purchased a new position in Oruka Therapeutics during the 3rd quarter worth $114,763,000. RTW Investments LP acquired a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at approximately $45,359,000. Franklin Resources Inc. purchased a new stake in shares of Oruka Therapeutics in the third quarter valued at approximately $17,661,000. Braidwell LP acquired a new position in Oruka Therapeutics during the third quarter worth $12,640,000. Finally, Great Point Partners LLC purchased a new position in Oruka Therapeutics in the third quarter worth $12,614,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Stock Performance

NASDAQ:ORKA opened at $21.73 on Monday. The company has a fifty day moving average of $25.60. Oruka Therapeutics has a 12-month low of $18.20 and a 12-month high of $53.88. The stock has a market capitalization of $760.55 million, a price-to-earnings ratio of -3.47 and a beta of 0.87.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.